Last updated: June 17, 2026
ecutive summary
Novo Nordisk Inc. v. Apotex Inc., No. 1:24-cv-09729 (D. Del.), is an ANDA patent-infringement dispute that fits the typical U.S. framework for Paragraph IV. The case caption confirms only parties and venue, not the asserted drug, patents, claims, or procedural posture. Without the underlying complaint, patent list, or docket entries, a litigation summary and merits analysis cannot be produced in a way that is complete and accurate.
NOVO NORDISK INC. v. APOTEX INC. 1:24-cv-09729 Litigation Summary: What Patents Were Asserted and Who Filed What Under the Hatch-Waxman Framework?
What is the procedural posture of Novo Nordisk v. Apotex in 1:24-cv-09729
A litigation summary requires docket-specific facts such as complaint filing date, answer and counterclaims, early motions (dismissal, claim construction), Markman schedule, expert deadlines, and any stipulated schedule or stay. Those data are not available from the case identifier alone.
Which patents does Novo Nordisk assert against Apotex in 1:24-cv-09729
A meaningful “what patents” section requires the actual asserted U.S. patent numbers and expiration dates, plus claim numbers tied to the asserted method, formulation, or composition. The case number does not provide the patent list.
Are the asserted patents method-of-use, formulation, or composition-of-matter
A correct classification depends on the claims asserted in the complaint and the technology description in the patents. The case identifier does not disclose that mapping.
Which drug is at issue in 1:24-cv-09729
Litigation analysis depends on the reference listed drug, NDA/ANDA number, and the Orange Book entry tied to the patents. That information is not included in the identifier.
Paragraph IV litigation risk and ANDA triggers: How does 1:24-cv-09729 fit typical generic entry timelines?
When does the asserted patent estate expire and what generic entry risk exists
To compute exclusivity and launch windows, the analysis needs:
- asserted patent expiration dates and any terminal disclaimers,
- pediatric exclusivity or other patent term extensions,
- Orange Book patent listing types and scopes,
- whether the case involves 30-month stay, settlements, or an injunction.
No expiration or exclusivity data are available from the case identifier alone.
Does 1:24-cv-09729 involve a 30-month stay or an earlier generic launch
Whether a stay applies and whether it was triggered requires ANDA filing date, notice date, and litigation timeline. Those elements are absent.
What is the Orange Book status of the Novo Nordisk drug in 1:24-cv-09729?
Which Orange Book patents are listed for the reference drug
Orange Book status requires the RLD and the listed patents with their expiration dates. The case identifier does not disclose the RLD.
Is the listed portfolio heavy on formulation, manufacturing, or dosing regimen patents
A “portfolio density” view requires the listed patent counts and categories for the RLD. Those data are not available.
What patent litigation outcomes matter most for investors and competitors in 1:24-cv-09729?
If Novo Nordisk wins, what remedies are likely
Remedies in ANDA cases can include permanent injunction, limited exclusion orders, and enhanced damages for willfulness. Determining likely scope requires knowing the court’s claim construction and trial posture, which is not available.
If Apotex wins or the case is dismissed, what is the launch pathway
Launch pathway analysis depends on whether patents are found non-infringed or invalid, whether any partial infringement findings occurred, and whether appeal was filed. None of that is disclosed.
Settlement and licensing analysis: Did Novo Nordisk and Apotex reach an agreement in 1:24-cv-09729?
Were there stay-and-settlement terms impacting 180-day exclusivity or launch timing
Settlement terms require docket filings and/or press releases, including any non-infringement stipulations, carve-outs, or agreed launch dates. The case identifier alone does not provide that.
Does any settlement mention covenant-not-to-sue or delayed launch
Covenant terms and scope are facts from filings. No filings are provided.
How strong is the patent estate for the Novo Nordisk product at issue in 1:24-cv-09729?
How to score strength: infringement vulnerability, obviousness risk, and claim breadth
A strength analysis requires:
- the asserted claim language,
- cited prior art,
- prosecution history and claim amendments,
- known co-pending litigations on the same patents.
Those elements are not available.
Key Takeaways
- No litigation summary or merits analysis can be produced from the case identifier alone.
- A complete and accurate report requires asserted patent numbers, the RLD/ANDA context, and docket-specific procedural facts, none of which are available in the provided input.
FAQs
- What does the case number 1:24-cv-09729 indicate about whether the dispute is an ANDA Paragraph IV?
- How do I determine which patents were asserted in a Novo Nordisk v. Apotex ANDA case?
- What court orders typically drive timelines in Hatch-Waxman cases?
- How is Orange Book exclusivity linked to infringement outcomes in ANDA litigation?
- What settlement terms most affect generic launch timing in Paragraph IV cases?
References
(No sources were cited because the provided input does not include case docket content, complaint details, or patent lists.)
